Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Immutep Ltd ( (AU:IMM) ) has issued an announcement.
Immutep Limited has made significant progress in its clinical trials, particularly with the TACTI-004 Phase III trial for non-small cell lung cancer (NSCLC), where the first patient has been successfully dosed. This trial, along with others like INSIGHT-003 and EFTISARC-NEO, underscores Immutep’s commitment to advancing its eftilagimod alfa (efti) in combination with KEYTRUDA® and other therapies. The company’s strong cash position supports its ongoing research and development efforts, positioning it well in the competitive biotechnology industry. These advancements could potentially lead to new treatment options for cancer patients and enhance Immutep’s market presence.
More about Immutep Ltd
Immutep Limited is a clinical-stage biotechnology company focused on developing novel LAG-3 immunotherapies for cancer and autoimmune diseases. The company’s primary products include eftilagimod alfa (efti), a first-in-class MHC Class II agonist, and IMP761, an agonist LAG-3 antibody. Immutep operates in the oncology and autoimmune disease sectors, aiming to address unmet medical needs through innovative treatments.
YTD Price Performance: -9.09%
Average Trading Volume: 5,000
Technical Sentiment Signal: Strong Buy
Current Market Cap: $233M
See more data about IMM stock on TipRanks’ Stock Analysis page.